David Dukhan

Inventor

Add to Portfolio

Stats

Details

Work History

Patent OwnerApplications FiledYear
UNIVERSITE DE MONTPELLIER
2
4
2
2013
2014
2015
UNIVERSITÉ DE MONTPELLIER
2
2012
CENTRE NATIONAL DA LA RECHERCHE SCIENTIFIQUE (CNRS)
1
2004
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
1
1
2
2
4
3
2006
2008
2012
2013
2014
2015
IDENIX PHARMACEUTICALS LLC
4
6
6
8
5
2010
2012
2013
2014
2015
MERCK SHARP & DOHME CORP.
1
2014
L'UNIVERSITE MONTPELLIER II
1
1
2004
2005
CECENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
1
2014
IDENIX PHARMACEUTICALS, INC.
1
1
2
2006
2012
2014
UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNOLOGIE
3
1
2014
2015
Indenix Pharmaceuticals, Inc.
1
2014
UNIVERSITE MONTPELLIER 2
1
1
2008
2014
UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
2
1
2013
2015

Inventor Addresses

AddressDuration
Montepellier, FRJun 28, 18 - Jun 28, 18
Montpellier Cedex 4, FRJul 26, 18 - Jul 26, 18
Montpellier, FRApr 07, 05 - May 02, 24
Saint Gely du Fesc, FRJun 23, 11 - Sep 08, 20
St Gely du Fesc, FRMar 29, 16 - Mar 29, 16
St Gely du Fresc, FRSep 16, 10 - Jun 05, 12
St. Gely du Fesc, FRMar 24, 16 - Jul 21, 20

Technology Profile

Technology Matters
A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 4
A61K: PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 37
A61P: THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 19

See more…

Patents / Publication

Patents / Publication #Year of Publication / IssuedTitleCitations
2024/0139,3252024ANTI-VIRAL AND HEPATIC-TARGETED DRUGS0
117307482023Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases0
2022/0040,2142022CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES1
2021/0205,3392021CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES0
108997882021Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases1

See more…


We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
> Upgrade to our Level for up to -1 portfolios!.